At the midpoint of 2023, biopharmaceutical merger-and-acquisition deals valued at $1bn or more are on a pace to demolish the levels seen annually from 2019 to 2022, and analysts from PwC predict more of that in the second half of the year. Just don’t expect a slew of big deals like the 13 March announcement that Pfizer Inc. is buying cancer antibody-drug conjugate (ADC) specialist Seagen Inc. for $43bn.
Biopharma M&A’s Busy Pace Expected To Continue During 2023’s Second Half
Analysts from PwC see multiple factors that should continue to drive bolt-on deals valued at $1bn or more, but heightened FTC scrutiny of large M&A may discourage bigger transactions.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.